Tiff Caza
@glombandit.bsky.social
I am a kidney pathologist and researcher seeking personal and professional growth. I work at Arkana Labs, but posts are my own opinions.
If you're a working pathologist looking to either undergo a career change or explore a new subspecialty (without having to undergo scutwork), reach out to us about our Mid-career Transition Program. This program is tailored to each pathologist and their needs. #renal #pathology #pathsky
Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
nephjc.com
We're excited to share a new research publication featuring @glombandit.bsky.social alongside collaborators from the NIH and Meharry Medical College. Read the publication here: pubmed.ncbi.nlm.nih.gov/42315018/ #renalresearch #kidneyresearch #nephsky
Painting pathology - an IgA nephropathy showing mesangial hypercellularity, endocapillary hypercellularity, and a crescent. 🎨
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
Do you biopsy pts with diabetes? Are you looking for diabetic nephropathy or something else? Check out the blog by @dramiliflores.bsky.social and Dr. Priya John #NephSky #MedSky 📣Now with a "audio abstract" at the top, preview if you want to read more! www.nephjc.com/news/2026/6/1/kidneybiopsy-dkd
Is all kidney disease in Diabetics "Diabetic Nephropathy"? — NephJC
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
nephjc.com
We're excited to share a new research publication from Dr. Jon Wilson, @glombandit.bsky.social, Dr. Randy Haun, and Dr. Chris Larsen titled "Framework for Apolipoprotein 1-Mediated Kidney Disease Classification." Read here: https://www.kireports.org/article/S2468-0249(26)02639-2/fulltext #nephsky
Framework for Apolipoprotein 1-Mediated Kidney Disease Classification
Black Americans have an increased risk of chronic kidney disease (CKD) compared with individuals without African ancestry. Variants designated G1 and G2 in the apolipoprotein L1 protein encoded by the APOL1 gene are a major contributor to this increased risk.1 These variants arose independently, rar...
kireports.org
We're proud to share a new publication with @aaronstorey.bsky.social, Dr. Patrick Walker, Dr. Chris Larsen, and @glombandit.bsky.social, titled "Serine Protease HTRA1 is a Common Autoantigen in Membranous Nephropathy in Patients of 80 Years and Older."
Serine Protease HTRA1 is a Common Autoantigen in Membranous Nephropathy in Patients of 80 Years and Older - PubMed
HTRA1 is a common autoantigen in PLA2R-negative MN among very elderly patients, occurring in approximately one in five cases aged 80 years or more. These findings support inclusion of HTRA1 testing in diagnostic evaluation of antigen-negative MN in patients 80 years and older and suggest the existen …
pubmed.ncbi.nlm.nih.gov
We're excited to share a new research publication from @aaronstorey.bsky.social, @glombandit.bsky.social, and Dr. Chris Larsen titled, "Proteomic Profiling of Complement Components in Glomerular Disease." Read here: https://pubmed.ncbi.nlm.nih.gov/41720186/ #ArkanaResearch #RenalPath #RenalResearch
Proteomic Profiling of Complement Components in Glomerular Disease - PubMed
The complement system plays a central role in glomerular disease development and resolution. Currently, renal biopsies assess the presence of complement through limited immunofluorescence stains (C3 and C1q). With more than 50 total proteins and fragments involved in the complement cascade, this met …
pubmed.ncbi.nlm.nih.gov
It's 2026!🎉 We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST. Join us on TWITTER (it will always be Twitter to us). Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down. www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025
Top Stories in Nephrology 2025 — NephJC
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
nephjc.com
IgG3κ Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency bit.ly/3Le1OFK
@nephrosharma.bsky.social and @glombandit.bsky.social sat down with Dr. Salil Parikh, a radiologist who helped his facility improve their adequacy rates significantly, to discuss one possible blueprint for better renal biopsies. #nephsky #radiology Listen to the conversation here:
Glom Goals: A Blueprint for Better Renal Biopsies
YouTube video by Arkana Laboratories
youtube.com
IgA Vasculitis A kidney biopsy is mandatory in patients with persistent proteinuria ≥0.5 g/day for more than 4 weeks, impaired kidney function, or suspicion of rapidly progressive glomerulonephritis (RPGN). #NephJC
The evidence of immunomodulatory effects of steroids and Nefecon comes from the following trials. High dose steroids treatment suffered from complications like infections. Nefecon, however, still showed similar systemic side-effects of other oral steroids. #NephJC
Treatment Approach: 💊 Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach. a) Generic responses to HTN/proteinuria b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Global Implementation of IgAN 2025 guidelines: #NephJC As we learn more and develop new treatments, it is important to try to make these available to a wide population of patients. Including low-income patients in future studies might allow for at least some access to cutting edge therapies.
First things first — where the story starts! Time to unpack the 4-hit hypothesis of IgA nephropathy — understanding each step opens doors to new treatments. #NephJC
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC www.nephjc.com/news/...
There is a 13-year gap between the approval of new drugs for use in adults and their approval in children. Could extrapolation accelerate clinical trials in pediatric nephrology? Read more in #ASNKidneyNews kidney.pub/KN1710-10
Did you know inadequate renal biopsies are on the rise? Recently, Dr. Shree Sharma and @glombandit.bsky.social sat down with Dr. Vandana Niyyar, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social to discuss renal biopsy adequacy and understand why it matters. Listen to the conversation:
Renal biopsy adequacy
open.spotify.com
In the latest episode of Visiting Joel, our visiting scholar, Dr. Evgeniya Pasternak, works with @glombandit.bsky.social on a research article. #pathresident #renalpath #renalrotation Here's a link to the latest episode:
Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
youtu.be
Up next! ☀️📚 We're taking a short break from trials, but don’t go far— #NephJC Summer Book Club is back! We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖
T3j 🧘 eGFRdiff is weakly/not affected by 🚫 Fat free lean muscle mass 🚫 Inflammation 🚫 Shrunken pore syndrome 🚫 Obesity 💡 This lack of alteration due to systemic issues makes eGFRdiff attractive for use in a wide variety of patients. #NephJC
Inflammation—> increase CRP —-> CRP affects Cystatin C —> reduced Cystatin C eGFR —> negative eGFRdiff #NephJC
T2f Let's deep into the prospective analysis 🥽 For each 10 mL/min ↑ in eGFRdiff 🚨20% ↓ mortality risk (AHR 0.80 [95% CI: 0.74–0.88]) 🚨17% ↓ HF risk (AHR 0.83 [95% CI: 0.73–0.94]) ✅ Association held after adjustment for muscle mass & filtration markers. What do we think? #NephJC
T0f So why does this matter? A more negative eGFRdiff (eGFRcr > eGFRcys) is linked to: 🫀 Cardiovascular disease 🧬 Frailty 💓 Heart failure ⚰️ Mortality #NephJC
T0e But muscle mass isn’t the whole story. 🧨 Factors contributing to eGFRdiff include: Chronic inflammation Endothelial dysfunction Shrunken pore syndrome Obesity Smoking Corticosteroids Which others do you consider? #NephJC
